Chemistry:Romaciclib
From HandWiki
Romaciclib is an investigational new drug being evaluated by Ryvu Therapeutics for the treatment of acute myeloid leukaemia (AML). It is a dual inhibitor of CDK8 and CDK19.[1][2][3]
References
- ↑ "Romaciclib - Ryvu Therapeutics". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800035316.
- ↑ "Clinical development of a CDK8/19 kinase inhibitor for acute myeloid leukemia". Expert Opinion on Investigational Drugs 35 (4): 253–256. April 2026. doi:10.1080/13543784.2026.2656430. PMID 41931045.
- ↑ Pakulska U, Obacz M, Woźnicki J, Wiklik K, Chakraborty S, Micek M, Mohanty V, Coelho D, Adamczyk E, Gołas A, Moszyńska A, Zhang H, Cybulska-Lubak M, Kaniuga E, Sandowska-Markiewicz Z, Konopleva M, Mikula M, Juszczyński P, Shastri A, Baran N, Rzymski T, Mazan M (January 2026). "Romaciclib, a CDK8/CDK19 inhibitor, can overcome venetoclax resistance through a combinatorial strategy". bioRxiv 10.64898/2025.12.16.693978.
{{cite bioRxiv}}: Check|biorxiv=value (help)
 |  |
